David Strobl
@drmurke.bsky.social
All things art and internal medicine (primary interest in cardiokidneymetabolic syndrome (Diabetes, CKD, Electrolyte Disorders, Heart Failure, Lipids etc)). Based in Vienna.
Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement. Read more in #Endocrine Reviews: https://bit.ly/46tf4Oq @endocrinesociety.bsky.social
Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement
Abstract. The medical management of obesity has been transformed by the introduction of obesity medicines (OMs), based on the actions of glucagon-like pept
bit.ly
🆕 EASL-EASD-EASO guidance on resmetirom and semaglutide as #MASH-targeted therapy 💉#Semaglutide: preferred in patients with obesity, T2D or high cardiovascular risk 💊#Resmetirom: prioritised in those without obesity or unable to use GLP-1RAs 🔗https://bit.ly/4ynVQpR
📖 Consensus Report Update for Managing Type 1 Diabetes in Adults. Building on the 2021 @easdnews.bsky.social & @amdiabetesassn.bsky.social report, this report provides updated guidance on managing #t1d in adults, with a focus on integrating new technologies. 🔗👉 link.springer.com/article/10.1...
In this Review, Sophie Monnerat and colleagues discuss the causes and treatment of hyponatraemia in older people (£) go.nature.com/4zfIUms #MedSky #EndoSky
Beyond #eGFR and #Albuminuria: Biological Pathways and Multiomics in #Cardiovascular–#Kidney–#Metabolic #Disease https://doi.org/10.1016/j.ekir.2026.106592 #KIRReview
An interesting review in @CircRes especially with our fastest growing demographic - Elders or SuperAgers❤️ Mechanisms for Mineralocorticoid-Driven Age-Related #Hypertension: Potential Therapeutic Role of #MRAs & #ASIs www.ahajournals.org/doi/10.1161/...
Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors | Circulation Research
Hypertension prevalence rises dramatically with advancing age, is not well controlled with current therapy, and contributes substantially to cardiovascular, renal, and neurological disorders that are ...
ahajournals.org
Primary Aldosteronism www.nature.com/articles/s41...
Primary aldosteronism - Nature Reviews Disease Primers
In this Primer, Vaidya and colleagues review the epidemiology, pathophysiology, diagnosis, management and quality of life of patients with primary aldosteronism, an important cause of hypertension res...
nature.com
The AHA/ACC/ADA/ASN have developed the first-ever guideline aimed at preventing & managing #CKM syndrome, an interconnected set of health conditions that significantly increase the risk of multiorgan complications & negative CV outcomes. https://bit.ly/4vvaJ7C #JACC #ClinicalGuidelines #CardioSky
Are you still interested in contrast and AKI? @markusathome.bsky.social and @gunnarheine.bsky.social invited me to pontificate Watch it here youtu.be/ZhJTKnm8iZg #NephSky
CM-induced AKI: Myth or Reality? Prof. Dr. Swapnil Hiremath (Ottawa, Canada)
YouTube video by MARKUS at HOMe
youtu.be
A discrepancy between cystatin C- and creatinine-based eGFR identifies early risk of heart failure, peripheral artery disease, and mortality in individuals with type 1 diabetes without albuminuria. Read here ➡️ doi.org/10.2337/dc25-2987
FIND CKD meets primary outcome (GFR slope) in n ~ 1500 with proteinuric non-diabetic CKD Bayer press release: www.bayer.com/media/en-us/... BL data + design paper pubmed.ncbi.nlm.nih.gov/38858818/ in NDT H/T Brendon Neuen on LinkedIn (!)
Saline Doesn’t Ruin Hyponatremia Labs (and it might help) How many times have you been evaluating a patient in the ED and bemoaned the sneaky liter of saline they got before anyone sent some urine for analysis. Turns out it doesn't ruin the labs at all. pbfluids.com/2026/03/sali...
Saline Doesn’t Ruin Hyponatremia Labs (It Might Help)
A study by Dr. Chienwichai highlights challenges in diagnosing hyponatremia due to undisclosed intravenous saline administration. While saline infusion does not obscure urine biochemical tests, it …
pbfluids.com
In adults with type 1 diabetes and chronic kidney disease with albuminuria, the decrease in the urinary albumin-to-creatinine ratio was significantly greater with finerenone than with placebo. Full phase 3 FINE-ONE trial results: nej.md/4rTPAmu #MedSky #EndoSky #Nephrology
Lower eGFR in type 1 diabetes doesn't appear to raise DKA risk. This encourages research into drugs like SGLTi, which may increase DKA risk but offer crucial kidney protection. Read here ➡️ doi.org/10.2337/dc25-1955
Featured in our March issue: Ming-Hua Zheng and colleagues review the connections between MASLD, sarcopenia and metabolic syndrome and discuss how care for patients affected by these diseases is evolving rdcu.be/e4fae #EndoSky #MedSky
Wir durften als Young Diabetologists die 1. Winter School für Kolleg:innen veranstalten: Im Programm gab es praxisrelevante Workshops & Fortbildung zu medizinischer Gesprächsführung. 🤓🏔️📚💉Auch eine weitere Folge für Öglykäm wurde aufgezeichnet. 🎧 @yd-austria.bsky.social
Almost all side effects on statin labels not caused by statins, finds major meta-analysis; authors call for labels to be updated. Find out more 👉 spkl.io/63324AsjHO
From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 #Diabetes Mellitus and #CKD https://doi.org/10.1016/j.ekir.2025.09.027 #KIRReview
🎬Episode 7 of Best of #EASD2025 is live! Dr. Michael Leutner (Medical University of Vienna) shares his key highlights, focusing on the SOUL trial and new insights into #HeartFailure and peripheral artery disease in #T2D. 🎥Watch👉 youtu.be/EgoIFh2bT-M?... #Diabetes #DiabetesResearch
Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) ca. 2026 from @kdigo.org #Nephpearls #NephSky 👉 kdigo.org/guidelines/a...
This is big and a very long time coming! Your TBR pile just got 100 years longer. www.newyorker.com/news/press-r...
The Entire New Yorker Archive Is Now Fully Digitized
For the first time, every cover, article, and issue in the magazine’s hundred-year history can be enjoyed on newyorker.com.
newyorker.com
Yes. This is a game changer. Beyond being able to replace AVS, it allows one to “see” the underlying pathological contributors to a large proportion of “idiopathic” hypertension. This is another piece of evidence that should make clinicians rethink the pathogenesis and treatment of hypertension
😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!) 🤝Well-aligned with @easlnews.bsky.social CPGs 😟Reimbursement currently restricted to semaglutide for T2DM 🤔Reimbursement in your country? 🖇️: rdcu.be/eLAde #LiverSky @georg-semmler.bsky.social
Paper of the Month#62 Es mehrt sich die Evidenz zur Effektivität von GLP1 RA bei Menschen mit T1D. Dieses Mal berichten wir über eine Studie bei denen Semaglutide bei (vorwiegend adipösen) Menschen m. T1D unter Pumpen/AID Systemen eingesetzt wurde Link zum PotM: 🖇️: www.pdffiller.com/s/Z2_qi9tBEB
Log In - pdfFiller
pdffiller.com
Core Curriculum by Biff F. Palmer and Deborah J. Clegg: Mixed Acid-Base Disturbances: Core Curriculum 2025 bit.ly/Palmer25CC (FREE)
New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis thelancet.com/journals/lan... #SGLT2 inhibitor #CKD #OpenAccess #MedSky #EndoSky #RenalSky
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis
SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status,...
thelancet.com